PREDICTION OF PROGRESSION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS

2019 ◽  
pp. 127-129
Author(s):  
U. K. Kamilova ◽  
M. M. Saidova
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease

scholarly journals Plasma expression of microRNA-425-5p and microRNA-451a as biomarkers of cardiovascular disease in rheumatoid arthritis patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Delia Taverner ◽  
Dídac Llop ◽  
Roser Rosales ◽  
Raimon Ferré ◽  
Luis Masana ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Disease Risk ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Media Thickness ◽  
Epigenetic Biomarkers

AbstractTo validate in a cohort of 214 rheumatoid arthritis patients a panel of 10 plasmatic microRNAs, which we previously identified and that can facilitate earlier diagnosis of cardiovascular disease in rheumatoid arthritis patients. We identified 10 plasma miRs that were downregulated in male rheumatoid arthritis patients and in patients with acute myocardial infarction compared to controls suggesting that these microRNAs could be epigenetic biomarkers for cardiovascular disease in rheumatoid arthritis patients. Six of those microRNAs were validated in independent plasma samples from 214 rheumatoid arthritis patients and levels of expression were associated with surrogate markers of cardiovascular disease (carotid intima-media thickness, plaque formation, pulse wave velocity and distensibility) and with prior cardiovascular disease. Multivariate analyses adjusted for traditional confounders and treatments showed that decreased expression of microRNA-425-5p in men and decreased expression of microRNA-451 in women were significantly associated with increased (β = 0.072; p = 0.017) and decreased carotid intima-media thickness (β = −0.05; p = 0.013), respectively. MicroRNA-425-5p and microRNA-451 also increased the accuracy to discriminate patients with pathological carotid intima-media thickness by 1.8% (p = 0.036) in men and 3.5% (p = 0.027) in women, respectively. In addition, microRNA-425-5p increased the accuracy to discriminate male patients with prior cardiovascular disease by 3% (p = 0.008). Additionally, decreased expression of microRNA-451 was significantly associated with decreased pulse wave velocity (β = −0.72; p = 0.035) in overall rheumatoid arthritis population. Distensibility showed no significant association with expression levels of the microRNAs studied. We provide evidence of a possible role of microRNA-425-5p and microRNA-451 as useful epigenetic biomarkers to assess cardiovascular disease risk in patients with rheumatoid arthritis.

scholarly journals Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies

2021 ◽  
Vol 14 ◽  
pp. 117954412110287
Author(s):  
Mir Sohail Fazeli ◽  
Vadim Khaychuk ◽  
Keith Wittstock ◽  
Boris Breznen ◽  
Grace Crocket ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Cardiovascular Disease ◽  
Literature Review ◽  
Rheumatoid Factor ◽  
Qualitative Evidence Synthesis ◽  
Cvd Risk ◽  
Rheumatoid Arthritis Risk ◽  
Published Evidence ◽  
Increased Risk

Objective: To scope the current published evidence on cardiovascular risk factors in rheumatoid arthritis (RA) focusing on the role of autoantibodies and the effect of antirheumatic agents. Methods: Two reviews were conducted in parallel: A targeted literature review (TLR) describing the risk factors associated with cardiovascular disease (CVD) in RA patients; and a systematic literature review (SLR) identifying and characterizing the association between autoantibody status and CVD risk in RA. A narrative synthesis of the evidence was carried out. Results: A total of 69 publications (49 in the TLR and 20 in the SLR) were included in the qualitative evidence synthesis. The most prevalent topic related to CVD risks in RA was inflammation as a shared mechanism behind both RA morbidity and atherosclerotic processes. Published evidence indicated that most of RA patients already had significant CV pathologies at the time of diagnosis, suggesting subclinical CVD may be developing before patients become symptomatic. Four types of autoantibodies (rheumatoid factor, anti-citrullinated peptide antibodies, anti-phospholipid autoantibodies, anti-lipoprotein autoantibodies) showed increased risk of specific cardiovascular events, such as higher risk of cardiovascular death in rheumatoid factor positive patients and higher risk of thrombosis in anti-phospholipid autoantibody positive patients. Conclusion: Autoantibodies appear to increase CVD risk; however, the magnitude of the increase and the types of CVD outcomes affected are still unclear. Prospective studies with larger populations are required to further understand and quantify the association, including the causal pathway, between specific risk factors and CVD outcomes in RA patients.

AB1140 ABNORMAL RIGHT VENTRICLE RESERVE FOLLOWING EXERCISE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1860.1-1860
Author(s):  
J. Zhang ◽  
T. Wu ◽  
R. Wu ◽  
J. Zhu
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
Stress Echocardiography ◽  
Treadmill Exercise ◽  
Physiological Stress ◽  
Exercise Stress ◽  
Healthy Controls ◽  
Right Heart ◽  
Right Heart Dysfunction ◽  
Rv Function

Background:Recent studies have indicated that cardiac autonomic dysfunction is an early sign of cardiovascular impairment in patients with connective tissue disease (CTD). Previous studies have mainly focused on autonomic regulation during rest in this population. The cardiac autonomic responses to an acute physiological stress might provide additional information on the autonomic dysfunction, serving as a powerful predictor of cardiovascular disease and mortality in patients with CTD.Objectives:We aimed to use exercise stress echocardiography to detect early right heart dysfunction in patients with CTD and healthy controls.Methods:Treadmill exercise stress echocardiography was performed in 19 CTD patients (8 systemic sclerosis, 6 mixed CTD and 5 SLE) and 20 healthy volunteers. Parameters of right ventricular (RV) systolic function (RV fractional area change, Doppler tissue s’ velocity, and systolic strain and strain rate) and diastolic function (peak E and A velocity, Doppler tissue e’, a’ and early and late diastolic strain rate) were evaluated at baseline and after exercise, with the difference (Δ) being systolic and diastolic reserve. The immunoblotting assay was performed to detect the levels of rheumatoid factor (RF) and C-reactive protein (CRP) as well as autoantibodies such as, antinuclear antibody (ANA), anti-U1 ribonucleoproteins (U1RNP), anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, anti-SCL-70 and RO-52. The correlation between these proteins and RV function was analyzed.Results:Both the patients with CTD and healthy controls had a normal range of BMI, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG). The average age of patients with CTD was 46.0 ± 10.4 years. At baseline, these patients presented no cardiovascular disease or pulmonary hypertension. No significant difference in the body weight, height, age, sex, blood pressure, RV and left ventricular (LV) function at rest between the two groups (allP>0.05). The parameters of RV systolic reserve decreased significantly in CTD group compared to those of the healthy controls (Δs’: 5.8±2.1 vs 8.3±2.5cm-1,P<0.01; ΔSr: 2.5±0.8 vs 2.8±0.7s-1,P<0.01). Consistently, RV diastolic reserve was significantly decreased in CTD patients compared to controls (Δe’: 2.8±1.5 vs 3.9±2.3cm-1,P<0.05; Δa’: 5.8±2.5 vs 10.9±6.3cm-1,P<0.05; ΔE-Sr: 0.8±0.2 vs 1.2±0.5s-1,P<0.05; ΔA-Sr: 0.9±0.3 vs 1.3±0.6s-1,P<0.05). To identify independent predictors of RV function in CTD patients, linear regression was conducted. This suggested that ANA, anti-U1RNP, anti-dsDNA, anti-Sm, anti-SSA, anti-SSB, anti-SCL-70 and RO-52 were not correlated with RV reserve (allP>0.05). A logistic regression analysis revealed that RF (P<0.05) and CRP (P<0.01) were independently associated with RV reserve in CTD patients in response to an acute physiological stress.Conclusion:Treadmill exercise echocardiography could detect right heart dysfunction early before diagnosed as cardiovascular diseases in patients with CTD. RV reserve after exercise might be a promising parameter to detect cardiovascular disease early in CTD patients.References:[1]Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis.Eur Heart J. 2017;38(22):1717–1727.[2]Peçanha T, Rodrigues R, Pinto AJ, et al. Chronotropic Incompetence and Reduced Heart Rate Recovery in Rheumatoid Arthritis.J Clin Rheumatol. 2018;24(7):375–380.Disclosure of Interests:None declared

scholarly journals Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis

2014 ◽  
Vol 34 (12) ◽  
pp. 2706-2716 ◽  
Author(s):  
Nuria Barbarroja ◽  
Carlos Pérez-Sanchez ◽  
Patricia Ruiz-Limon ◽  
Carmen Castro-Villegas ◽  
Maria Angeles Aguirre ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
Citrullinated Protein

scholarly journals Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease

2016 ◽  
Vol 68 (6) ◽  
pp. 1367-1376 ◽  
Author(s):  
Javier Rodríguez-Carrio ◽  
Raquel López-Mejías ◽  
Mercedes Alperi-López ◽  
Patricia López ◽  
Francisco J. Ballina-García ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Density ◽  
Paraoxonase 1

scholarly journals Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study

2021 ◽  
Vol 8 (4) ◽  
pp. 1-42
Author(s):  
Sven Plein ◽  
Bara Erhayiem ◽  
Graham Fent ◽  
Jacqueline Andrews ◽  
John Greenwood ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
Cardiovascular Magnetic Resonance ◽  
Magnetic Resonance ◽  
Confidence Interval ◽  
Early Rheumatoid Arthritis ◽  
Cardiovascular Magnetic Resonance Imaging ◽  
Aortic Distensibility ◽  
Control Subjects ◽  
Group 1

Background The VEDERA (Very Early vs. Delayed Etanercept in Rheumatoid Arthritis) randomised controlled trial compared the effect of conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy with biologic DMARD (bDMARD) therapy using the tumour necrosis factor inhibitor etanercept in treatment-naive, early rheumatoid arthritis patients. The CADERA (Coronary Artery Disease Evaluation in Rheumatoid Arthritis) trial was a bolt-on study in which VEDERA patients underwent cardiovascular magnetic resonance imaging to detect preclinical cardiovascular disease at baseline and following treatment. Objectives To evaluate whether or not patients with treatment-naive early rheumatoid arthritis have evidence of cardiovascular disease compared with matched control subjects; whether or not this is modifiable with DMARD therapy; and whether or not bDMARDs confer advantages over csDMARDs. Design The VEDERA patients underwent cardiovascular magnetic resonance imaging at baseline and at 1 and 2 years after treatment. Setting The setting was a tertiary centre rheumatology outpatient clinic and specialist cardiovascular magnetic resonance imaging unit. Participants Eighty-one patients completed all assessments at baseline, 71 completed all assessments at 1 year and 56 completed all assessments at 2 years. Patients had no history of cardiovascular disease, had had rheumatoid arthritis symptoms for ≤ 1 year, were DMARD treatment-naive and had a minimum Disease Activity Score-28 of 3.2. Thirty control subjects without cardiovascular disease were approximately individually matched by age and sex to the first 30 CADERA patients. Patients with a Disease Activity Score-28 of ≥ 2.6 at 48 weeks were considered non-responders. Interventions In the VEDERA trial patients were randomised to group 1, immediate etanercept and methotrexate, or group 2, methotrexate ± additional csDMARD therapy in a treat-to-target approach, with a switch to delayed etanercept and methotrexate in the event of failure to achieve clinical remission at 6 months. Main outcome measures The primary outcome measure was difference in baseline aortic distensibility between control subjects and the early rheumatoid arthritis group and the baseline to year 1 change in aortic distensibility in the early rheumatoid arthritis group. Secondary outcome measures were myocardial perfusion reserve, left ventricular strain and twist, left ventricular ejection fraction and left ventricular mass. Results Baseline aortic distensibility [geometric mean (95% confidence interval)] was significantly reduced in patients (n = 81) compared with control subjects (n = 30) [3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to 3.3 × 10–3/mmHg) vs. 4.4 × 10–3/mmHg (3.7 × 10–3/mmHg to 5.2 × 10–3/mmHg), respectively; p < 0.001]. Aortic distensibility [geometric mean (95% confidence interval)] improved significantly from baseline to year 1 across the whole patient cohort (n = 81, with imputation for missing values) [3.0 × 10–3/mmHg (2.7 × 10–3/mmHg to 3.4 × 10–3/mmHg) vs. 3.6 × 10–3/mmHg (3.1 × 10–3/mmHg to 4.1 × 10–3/mmHg), respectively; p < 0.001]. No significant difference in aortic distensibility improvement between baseline and year 1 was seen in the following comparisons (geometric means): group 1 (n = 40 at baseline) versus group 2 (n = 41 at baseline): 3.8 × 10–3/mmHg versus 3.4 × 10–3/mmHg, p = 0.49; combined groups 1 and 2 non-responders (n = 38) versus combined groups 1 and 2 responders (n = 43): 3.5 × 10–3/mmHg versus 3.6 × 10–3/mmHg, p = 0.87; group 1 non-responders (n = 17) versus group 1 responders (n = 23): 3.6 × 10–3/mmHg versus 3.9 × 10–3/mmHg, p = 0.73. There was a trend towards a 10–30% difference in aortic distensibility between (group 1) responders who received first-line etanercept (n = 23) and (group 2) responders who never received etanercept (n = 13): 3.9 × 10–3/mmHg versus 2.8 × 10–3/mmHg, p = 0.19; ratio 0.7 (95% confidence interval 0.4 to 1.2), p = 0.19; ratio adjusted for baseline aortic distensibility 0.8 (95% confidence interval 0.5 to 1.2), p = 0.29; ratio fully adjusted for baseline characteristics 0.9 (95% confidence interval 0.6 to 1.4), p = 0.56. Conclusions The CADERA establishes evidence of the vascular changes in early rheumatoid arthritis compared with controls and shows improvement of vascular changes with rheumatoid arthritis DMARD therapy. Response to rheumatoid arthritis therapy does not add further to modification of cardiovascular disease but, within the response to either strategy, etanercept/methotrexate may confer greater benefits over standard methotrexate/csDMARD therapy. Trial registration Current Controlled Trials ISRCTN89222125 and ClinicalTrials.gov NCT01295151. Funding This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership, and will be published in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 4. See the NIHR Journals Library website for further project information. Pfizer Inc. (New York, NY, USA) supported the parent study, VEDERA, through an investigator-sponsored research grant reference WS1092499.

Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis

2012 ◽  
Vol 73 (5) ◽  
pp. 543-546 ◽  
Author(s):  
Raquel López-Mejías ◽  
Mercedes García-Bermúdez ◽  
Carlos González-Juanatey ◽  
Santos Castañeda ◽  
José A. Miranda-Filloy ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease
Sign in / Sign up

Export Citation Format

Share Document